Novel Microdevices
Novel Microdevices is dedicated to revolutionizing clinical diagnostics through innovative, portable, and rapid testing solutions for infectious diseases. Their mission is to provide lab-quality results in less than 15 minutes at a cost-effective price, making diagnostics accessible especially in low-resource settings and underserved communities. The company's vision is to accelerate treatment decisions and improve healthcare outcomes worldwide by delivering advanced point-of-care molecular diagnostics.
Industries
Nr. of Employees
small (1-50)
Novel Microdevices
101 W Dickman St Ste 300, Baltimore, MD 21230
Patents
Automated point-of-care devices for complex sample processing and methods of use thereof
US-12151239-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
US-11364495-B2
View DetailsSample processing device comprising magnetic and mechanical actuating elements using linear or rotational motion and methods of use thereof
US-11260392-B2
View Details
Automated point-of-care devices for complex sample processing and methods of use thereof
US-12151239-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
US-11364495-B2
View DetailsSample processing device comprising magnetic and mechanical actuating elements using linear or rotational motion and methods of use thereof
US-11260392-B2
View DetailsProducts
Portable point-of-care molecular diagnostic system (in development)
A battery-powered, ultra-portable diagnostic instrument and associated single-use microfluidic cartridges that deliver lab-quality molecular test results at the point of care in approximately 15 minutes; platform intended for multiplexed detection of respiratory and sexually transmitted infections and for detection of resistance markers. The system and assays are under development and not available for sale.
Portable point-of-care molecular diagnostic system (in development)
A battery-powered, ultra-portable diagnostic instrument and associated single-use microfluidic cartridges that deliver lab-quality molecular test results at the point of care in approximately 15 minutes; platform intended for multiplexed detection of respiratory and sexually transmitted infections and for detection of resistance markers. The system and assays are under development and not available for sale.
Expertise Areas
- Point-of-care molecular diagnostics
- NAAT and RT-PCR assay development
- Microfluidic sample-to-answer assay integration
- Multiplex infectious disease testing
Key Technologies
- RT-PCR / NAAT
- Isothermal nucleic acid amplification
- Microfluidics
- Integrated lysis and solid-phase nucleic acid extraction
News & Updates
Novel Microdevices announced the award of an additional $2.68 million in follow-on funding from the NIH RADx® Tech program after achieving key milestones for its high-performance, point-of-care RT-PCR platform.
Novel Microdevices was awarded approximately $1.4 million from NIH RADx® to develop a next-generation, high-performance, point-of-care RT-PCR test that detects RSV, Influenza A, Influenza B, and COVID-19 in just 15 minutes.
Received over $13.8 million from CARB-X and NIH RADx® to develop rapid molecular diagnostic platforms for infectious diseases including STIs and respiratory illnesses.
Novel Microdevices announced the award of an additional $2.68 million in follow-on funding from the NIH RADx® Tech program after achieving key milestones for its high-performance, point-of-care RT-PCR platform.
Novel Microdevices was awarded approximately $1.4 million from NIH RADx® to develop a next-generation, high-performance, point-of-care RT-PCR test that detects RSV, Influenza A, Influenza B, and COVID-19 in just 15 minutes.
Received over $13.8 million from CARB-X and NIH RADx® to develop rapid molecular diagnostic platforms for infectious diseases including STIs and respiratory illnesses.